Vitality Biopharma receives FDA Orphan Drug Designation for VBX-100 for pediatric ulcerative colitis

RANGE IMPACT, INC.

FDA granted Orphan Drug Designation to VBX-100, a glycosylated cannabinoid prodrug, for pediatric ulcerative colitis.
Orphan Drug Designation provides seven-year market exclusivity upon FDA approval, tax credits, and fee exemptions.
Vitality has developed over 100 novel glycosylated cannabinoid compounds using proprietary enzymatic bioprocessing.
VBX-100 targets inflammatory conditions of the gastrointestinal tract; company plans to accelerate research.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.